RGX-314 for Wet AMD

Robert Avery MD, PhD

Show Description +

Robert L. Avery, MD, shares data from a phase 1/2a study that evaluated the safety and efficacy of RGX-314 (RegenxBio) for the treatment of wet AMD. Dr. Avery provides an update on the most recent readouts of the trial and previews forthcoming trials in wet AMD and diabetic retinopathy.

Posted: 10/05/2020

Keywords:

Clinical Cases

•

Diabetic Retinopathy

•

Gene Therapy

•

REGENXBIO

•

retina-meeting-recap

•

Wet AMD

Up Next

Name: RGX-314 for Wet AMD
Uploaded: 2020-10-05T14:57:00+00:00
Description: Robert L. Avery, MD, shares data from a phase 1/2a study that evaluated the safety and efficacy of RGX-314 (RegenxBio) for the treatment of wet AMD. Dr. Avery provides an update on the most recent readouts of the trial and previews forthcoming trials in wet AMD and diabetic retinopathy.